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Abstract 
Background: Gonadotropin-releasing hormone (GnRH) plays essential roles in 
embryo implantation, invasion of trophoblastic tissue, and steroid synthesis in the 
placenta. 
Objective: The aim of this study was to evaluate the effect of GnRH antagonist 
administration on pregnancy outcomes in early implantation period.  
Materials and Methods: In this retrospective study, 94 infertile women undergoing 
GnRH antagonist protocol who were at risk of ovarian hyperstimulation syndrome 
(OHSS) were included. Sixty-seven patients (group I) received Cetrorelix 0.25 
mg/daily in the luteal phase for 3 days while in 27 participants (group II), it was not 
administered. Pregnancy outcomes were assessed based on chemical and clinical 
pregnancy rates. 
Results: The pregnancy outcomes were not significantly different between two 
groups (p=0.224). 
Conclusion: The present study proposed that luteal phase GnRH antagonist 
administration does not influence the chance of successful pregnancy outcomes. 
 
Key words: Gonadotropin-releasing hormone antagonist, Pregnancy outcome, In vitro 
fertilization. 
 
Introduction 
 
emale genital tissues like ovary, 
endometrium, and placenta are extra 
pituitary tissues which express 
Gonadotropin-releasing hormone (GnRH) 
receptors (1). GnRH plays essential roles in 
embryo implantation, invasion of trophoblastic 
tissue, and steroid synthesis in the placenta 
(2). There are limited evidences of GnRH 
antagonists’ effects on pregnancy outcomes. 
Several protocols such as GnRH antagonist 
protocol were used for in vitro fertilization 
(IVF) (3, 4). Previous studies evaluated the 
role of GnRH antagonist in women with poor 
response to ovulation stimulation. Some 
studies were demonstrated GnRH antagonist 
is comparable with GnRH agonist (5, 6). The 
most important GnRH antagonist benefits are 
including: decrease the need of exogenous 
gonadotropin, shorter time for stimulation, and 
a cost effective protocol (3, 4, 7-9).  
Also GnRH antagonist causes the 
regression of established severe ovarian 
hyper stimulation syndrome (OHSS) by 
luteolysis as a key mechanism in prevention 
of OHSS (2). After introduction of GnRH 
antagonist into clinical practice, it reduced 
OHSS rate in IVF/ICSI cycles (9). GnRH 
antagonist can improve the poor response to 
ovulation stimulation (6, 10, 11). Although 
many studies showed the benefits of GnRH 
antagonist on IVF/ICSI cycle outcomes but its 
effect is controversial. The use of GnRH 
antagonists is generally limited to the last few 
days of ovulation in IVF/ICSI cycles.  
The aim of this study was to evaluate the 
GnRH antagonist effects at pharmacological 
doses given in early implantation period on 
pregnancy outcomes. 
 
Materials and methods 
 
In this retrospective study, medical records 
of 94 women that were at risk of OHSS in 
IVF/ICSI cycle and has been reffered to the 
Research and Clinical Center for Infertility, 
Yazd, Iran between October 2014 and 
February 2015 were reviewed. The study 
protocol was approved by the ethics 
committee of the Research and Clinical 
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Center for Infertility, Yazd, Iran and oral 
consent was obtained from all participants.  
Inclusion criteria were women under 40 
years old, having more than 20 follicles (>14 
mm) at triggering time, and on risk of OHSS 
during ICSI-IVF cycle with embryo transfer. 
Women with history of endometriosis, history 
of more than 2 implantation failure, and 
severe male factor were excluded.  
Totally, 94 eligible women were studied in 
two groups. All participants were treated with 
GnRH antagonist protocol. Patients received 
recombinant human follicle stimulating 
hormone (Gonal-F) (150 IU, subcutaneously) 
for 5 days. Serial trans-vaginal sonography 
was performed. When the mature follicle (≥14 
mm) was detected, GnRH antagonist 
(Cetrotide) (0.25 mg/daily, subcutaneously) 
was injected. Triggering was started with 1500 
IU hCG (Pregnyl, Organon, Netherland) and 
0.2 mg GnRH-a (Decapeptyl®, 0.1 mg) 
(subcutaneously) injection when at least two 
follicles with a mean diameter of 17 mm was 
observed.  
Trans-vaginal egg retrieval was done under 
sedation after 36 hrs. 67 women received 25 
mg Cetrotide subcutaneously for 3 days from 
day of oocyte retrieval (case group) and 27 
participants did not receive Cetrotide in luteal 
phase (control group). 2 embryos were 
transferred 48 hr after oocyte retrieval using 
an embryo transfer Labotect catheter 
(Labotect Gmbh. Lbabor-Technik-Göttingen 
GmbH, Gottingen, Germany) In all patients. 
All transferred embryos were in grade A and 
B. Progesterone suppositories (Cyclogest®) 
400 mg twice in a day was used vaginally on 
the day of oocyte collection for luteal phase 
support, and it continued until the fetal heart 
activity was documented by ultrasonography. 
Serum beta-hCG (β-hCG) was assessed on 
day 14 after embryo transfer. 
Positive pregnancy test was define as β-
hCG >50 IU/L. Pregnancy outcomes were 
assessed based on clinical pregnancy 
(observation of fetal heart activity by 
transvaginal ultrasonography 2-3 wks after 
positive β-hCG). Implantation rate was defined 
as the ratio of gestational sacs to the number 
of embryos transferred. 
 
Statistical analysis 
All of statistical analysis was done by 
SPSS 20 (SPSS, Chicago, IL). The normal 
distribution of data was checked. Mean±SD 
were calculated for descriptive analysis. 
Independent t-test and χ2 were used. The 
statistical significances considered as 0.05. 
According with power analysis the power of 
study was 0.8 and α was 0.05. 
 
Results 
 
The mean age of participants was 
28.56±4.03 yrs in case and 28.03±4.8 yrs in 
control group. Basic characteristics of 
participants in groups are shown in table I. 
There were not statistically differences in age, 
duration of infertility, basal FSH serum, 
progesterone and estradiol level in the day of 
HCG triggering between groups. While the 
mean number of embryo was different (Table 
I). The pregnancy outcome was not 
significantly different between case and 
control group (p=0.224). The implantation rate 
was 14.39% in case group and 9.25% in 
controls (p=0.089) (Table II). 
 
 
Table I. The basic characteristics of patients in two groups 
Variables Case group (n=67) Control group (n=27) p-value* 
Age (year) 28.56 ± 4.03 28.03 ± 4.8 0.593 
3rd day FSH level 5.76 ± 2.73 5.71 ± 3.42 0.942 
Infertility duration (year) 6.73 ± 3.85 6.66 ± 4.49 0.942 
Serum progesterone** (ng/ml) 1.09 ± 0.55 1.11 ± 0.55 0.924 
Serum estradiol** (pg/mL) 3337.07 ± 514.44 3301.63 ± 459.04 0.756 
Data are presented as mean±SD. 
*Independent Students’ t-Test   ** in the day of HCG triggering 
 
 
 
Table II. ART outcomes in two studied groups  
 Case group (n=67) Control group (n=27) p-value* 
Number of oocyte a 19.86 ± 4.94 18.51 ± 2.84 0.023 
Number of embryo a 6.31 ± 5.21 5.22 ± 4.06 0.332 
Clinical pregnancy rate b 19 (28.78%) 5 (18.51%) 0.224  
Implantation rate 14.39% 9.25% 0.089 
a: Data are presented as mean±SD.   b: Data are presented as n(%).   *χ2 test 
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Discussion 
 
Our results showed that luteal phase GnRH 
antagonist administration did not influence the 
chance of pregnancy. The clinical pregnancy 
rate in studied groups was not significantly 
different. Triggering of final oocyte maturation 
by hCG induces massive luteinization, 
increase angiogenic factors secretion (such as 
angiotensin II, interleukins, vascular 
endothelial growth factor, histamine, prolactin, 
prostaglandins, endothelin-1, and selectins) 
from corpus luteums of hyperstimulated 
ovaries. It leads to development of OHSS by 
increase in vascular permeability, and finally 
fluid shift to the third space (12-15). 
Previous studies reported that GnRH 
antagonist administration in the luteal phase 
improved severe OHSS in two days after 
injection of GnRH antagonist by decreasing 
the ovarian volume, hematocrit, ascites, and 
oestradiol and progesterone concentrations 
(3, 4, 8). It suggests a luteolytic effect of the 
GnRH antagonist that lead to a decrease of 
ovarian activity and angiogenic factors 
secretion, resulting in regression of severe 
OHSS (4, 8). “GnRH antagonist inhibits Matrix 
metalloproteinase (MMP) and therefore can 
disrupt the implantation. GnRH antagonist 
effect on the expression of HOXA10 genes in 
endometrium which is an important regulator 
of endometrial receptivity” (16). 
GnRH antagonist administration during 
peri-implantation period may cause some 
concern about the potential adverse effects of 
GnRH antagonist on embryo implantation, 
pregnancy and neonatal outcomes (11). Our 
findings showed that pregnancy rate is similar 
between two studied groups. There are few 
studies about the effect of luteal phase GnRH 
antagonist administration on pregnancy 
outcomes (8, 11, 12). Lainas et al in a 
prospective cohort study on 192 IVF patients 
who were at risk of OHSS showed that 
pregnancy and neonatal outcomes did not 
decrease after luteal GnRH antagonist 
administration (1). Some recent studies 
documented that GnRh antagonist 
administration is not associated with 
pregnancy or congenital adverse effects (1-4, 
8-11, 17-20).  
As our study limitations, OHSS evolution, 
neonate and children outcomes were not 
studied. Also the follow up period was very 
short.  
Conclusion 
 
In conclusion, luteal phase GnRH 
antagonist administration does not influence 
the chance of pregnancy after ART. The 
incidence of chemical and clinical pregnancy 
in groups was not significantly different. 
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